Beyond these approved agents, several ICIs are under investigation for laryngeal cancer, including dostarlimab (anti-PD-1), ipilimumab and tremelimumab (anti-CTLA-4), atezolizumab and durvalumab (anti-PD-L1), and lirilumab (anti-killer cell immunoglobulin-like receptor) [11]. This evidence concerns the gene PDCD1 and laryngeal carcinoma.